Skip to content
777 Sourcing.

Capability

in vivo validation

Suppliers
4
States & provinces
4
Countries
2

4 in vivo validation suppliers across 4 states and provinces in 2 countries. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

ADViRNA is a boutique contract research organization (CRO) specializing in RNAi and oligonucleotide therapeutics. It provides oligonucleotide design, synthesis, screening, custom assay development, and siRNA reagents, supporting research from target identification to in vivo validation.

ASO designchemical modificationsconjugationcustom assay developmentduplex annealingHPLC and Mass Spec verificationoligonucleotide designoligonucleotide screeningoligonucleotide synthesissiRNA design

ALMA AI, INC.

NEW YORK, NY

AlmaDyne is an AI-powered drug discovery company whose mission is to unlock undruggable targets by mapping the full conformational landscape of disease-relevant proteins in their native biological environment. It models the full dynamic range of proteins in native membrane or cytoplasmic environments to reveal transient conformations and hidden binding pockets, and validates AI-designed candidates in vitro and in vivo with Columbia and King's College London.

AI protein dynamics modelingconformational landscape mappingin vitro validationstructure-based drug design

BIOSYMETRICS INC

BETHESDA, MD

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data using machine learning to translate human disease biology and advance precision medicines. Its Elion platform connects patient data from electronic medical records with experimental data captured in zebrafish models using proprietary computer vision to identify high-confidence drug targets. The company is advancing programs in cardiometabolic, neurological, and rare diseases, including familial dilated cardiomyopathy, atherosclerosis, and epilepsy.

computer visiondrug discoverymachine learningphenomicstarget discovery

DIOSYNVAX LTD

CAMBRIDGE, Cambridgeshire

DIOSynVax customises vaccine antigen design to maximise protection against existing and future viruses. Its patent-protected method combines computational biology with in vitro and in vivo validation to select Vaccine Antigen Payload (VAP) candidates. The company targets high-consequence viruses including influenza, haemorrhagic fever, and coronaviruses such as SARS-CoV-2, and partners with leading organisations to advance vaccine solutions.

Artificial Intelligencecomputational biologyGenomicsimmunologyin vitro validationpreclinical and clinical testingsynthetic biology

Related capabilities

Other processes offered by the shops that list in vivo validation.

Browse all capabilities